Connection

Paolo Gisondi to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Paolo Gisondi has written about Antibodies, Monoclonal, Humanized.
Paolo Gisondi
Connection Strength
0.224
Antibodies, Monoclonal, Humanized
  1. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013 May; 168(5):1124-7.
    View in: PubMed
    Score: 0.109
  2. Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. J Eur Acad Dermatol Venereol. 2021 Nov; 35(11):e709-e711.
    View in: PubMed
    Score: 0.048
  3. Treatment Approaches to Moderate to Severe Psoriasis. Int J Mol Sci. 2017 Nov 16; 18(11).
    View in: PubMed
    Score: 0.037
  4. Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clin Exp Rheumatol. 2019 Jan-Feb; 37(1):133-136.
    View in: PubMed
    Score: 0.010
  5. Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo. 2017 Sep 21; 69(3):105-110.
    View in: PubMed
    Score: 0.009
  6. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017 Dec; 31(12):1951-1963.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.